Home Cart 0 Sign in  
X

[ CAS No. 1655-07-8 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
3d Animation Molecule Structure of 1655-07-8
Chemical Structure| 1655-07-8
Chemical Structure| 1655-07-8
Structure of 1655-07-8 * Storage: {[proInfo.prStorage]}
Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Quality Control of [ 1655-07-8 ]

Related Doc. of [ 1655-07-8 ]

Alternatived Products of [ 1655-07-8 ]

Product Details of [ 1655-07-8 ]

CAS No. :1655-07-8 MDL No. :MFCD00001631
Formula : C9H14O3 Boiling Point : -
Linear Structure Formula :- InChI Key :FGSGHBPKHFDJOP-UHFFFAOYSA-N
M.W : 170.21 Pubchem ID :95543
Synonyms :

Calculated chemistry of [ 1655-07-8 ]

Physicochemical Properties

Num. heavy atoms : 12
Num. arom. heavy atoms : 0
Fraction Csp3 : 0.78
Num. rotatable bonds : 3
Num. H-bond acceptors : 3.0
Num. H-bond donors : 0.0
Molar Refractivity : 44.75
TPSA : 43.37 Ų

Pharmacokinetics

GI absorption : High
BBB permeant : Yes
P-gp substrate : No
CYP1A2 inhibitor : No
CYP2C19 inhibitor : No
CYP2C9 inhibitor : No
CYP2D6 inhibitor : No
CYP3A4 inhibitor : No
Log Kp (skin permeation) : -6.33 cm/s

Lipophilicity

Log Po/w (iLOGP) : 1.81
Log Po/w (XLOGP3) : 1.42
Log Po/w (WLOGP) : 1.31
Log Po/w (MLOGP) : 0.9
Log Po/w (SILICOS-IT) : 1.82
Consensus Log Po/w : 1.45

Druglikeness

Lipinski : 0.0
Ghose : None
Veber : 0.0
Egan : 0.0
Muegge : 1.0
Bioavailability Score : 0.55

Water Solubility

Log S (ESOL) : -1.59
Solubility : 4.36 mg/ml ; 0.0256 mol/l
Class : Very soluble
Log S (Ali) : -1.94
Solubility : 1.97 mg/ml ; 0.0116 mol/l
Class : Very soluble
Log S (SILICOS-IT) : -1.68
Solubility : 3.55 mg/ml ; 0.0208 mol/l
Class : Soluble

Medicinal Chemistry

PAINS : 0.0 alert
Brenk : 1.0 alert
Leadlikeness : 1.0
Synthetic accessibility : 2.39

Safety of [ 1655-07-8 ]

Signal Word:Warning Class:N/A
Precautionary Statements:P261-P305+P351+P338 UN#:N/A
Hazard Statements:H315-H319-H335 Packing Group:N/A
GHS Pictogram:

Application In Synthesis of [ 1655-07-8 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Upstream synthesis route of [ 1655-07-8 ]
  • Downstream synthetic route of [ 1655-07-8 ]

[ 1655-07-8 ] Synthesis Path-Upstream   1~18

  • 1
  • [ 1655-07-8 ]
  • [ 858279-01-3 ]
Reference: [1] Helvetica Chimica Acta, 1945, vol. 28, p. 1684,1690
  • 2
  • [ 124-42-5 ]
  • [ 1655-07-8 ]
  • [ 19178-21-3 ]
Reference: [1] Patent: US5234936, 1993, A,
  • 3
  • [ 143-37-3 ]
  • [ 1655-07-8 ]
  • [ 19178-21-3 ]
Reference: [1] Journal of the American Chemical Society, 1952, vol. 74, p. 842
[2] Journal of the American Chemical Society, 1958, vol. 80, p. 6609,6611
  • 4
  • [ 1655-07-8 ]
  • [ 36556-02-2 ]
Reference: [1] Journal of the Chemical Society, 1932, p. 2426,2430
  • 5
  • [ 1655-07-8 ]
  • [ 34170-21-3 ]
Reference: [1] Journal of the Chemical Society, 1946, p. 362,365
  • 6
  • [ 2986-19-8 ]
  • [ 1655-07-8 ]
  • [ 34170-21-3 ]
Reference: [1] Journal of Organic Chemistry, 1959, vol. 24, p. 922,924
[2] Journal of the Chemical Society, 1946, p. 362,365
  • 7
  • [ 1655-07-8 ]
  • [ 1139-83-9 ]
Reference: [1] ChemMedChem, 2010, vol. 5, # 9, p. 1616 - 1630
  • 8
  • [ 1655-07-8 ]
  • [ 49843-98-3 ]
Reference: [1] Journal of Medicinal Chemistry, 2005, vol. 48, # 25, p. 8045 - 8054
[2] Journal of Medicinal Chemistry, 2005, vol. 48, # 25, p. 8045 - 8054
[3] Patent: WO2013/57258, 2013, A1,
[4] Patent: US2017/190664, 2017, A1,
[5] Patent: US2005/256181, 2005, A1,
  • 9
  • [ 1655-07-8 ]
  • [ 1127-85-1 ]
Reference: [1] Journal of Medicinal Chemistry, 1994, vol. 37, # 22, p. 3828 - 3833
[2] Patent: WO2014/149164, 2014, A1,
[3] Journal of Medicinal Chemistry, 2015, vol. 58, # 24, p. 9480 - 9497
[4] Patent: US2016/90374, 2016, A1,
[5] Patent: KR101730790, 2017, B1,
  • 10
  • [ 1655-07-8 ]
  • [ 56517-59-0 ]
Reference: [1] Chemistry of Heterocyclic Compounds, 2006, vol. 42, # 6, p. 765 - 775
  • 11
  • [ 1655-07-8 ]
  • [ 1461-96-7 ]
YieldReaction ConditionsOperation in experiment
63%
Stage #1: With bromine In chloroform at 0 - 20℃;
Stage #2: With potassium hydroxide In water at 0℃; for 6 h;
Stage #3: With hydrogenchloride In water
Br2 (112.8 g, 705.6 mmol) was added dropwise at 0 °C to a solution of ethyl 2- oxocyclohexanecarboxylate (120 g, 705.6 mmol) in chloroform (360 ml). The resulting reaction mixture was stirred at rt overnight, then washed with NaHC03 (2x200 ml) and brine (2x100 ml). The organic layer was dried over Na2S04 and concentrated and the residue was added dropwise to an ice-cold solution of KOH (168 g, 3 mol) in water (960 ml). The reaction mixture was stirred for 6 h at 0 °C, then extracted with diethyl ether. The aqueous phase was acidified with 4.0 M HCI (pH 5) and extracted with diethyl ether. The combined organic layers were washed with brine (200 ml), dried, filtered and concentrated. The afforded yellow oil was crystallized (EtOAc/diethyl ether) which gave the title compound as a colourless crystals (70 g, 63percent). MS (ESI): 159 [M+H]+.
Reference: [1] Tetrahedron Letters, 2007, vol. 48, # 4, p. 635 - 638
[2] Patent: WO2013/95275, 2013, A1, . Location in patent: Page/Page column 35
[3] Journal of the American Chemical Society, 2000, vol. 122, # 50, p. 12610 - 12611
[4] Journal of Organic Chemistry, 1989, vol. 54, # 4, p. 817 - 824
[5] Journal of Organic Chemistry, 1961, vol. 26, p. 22 - 27
[6] Journal of Medicinal Chemistry, 2008, vol. 51, # 3, p. 380 - 383
[7] Patent: WO2007/137107, 2007, A2, . Location in patent: Page/Page column 54
  • 12
  • [ 1655-07-8 ]
  • [ 1128-00-3 ]
YieldReaction ConditionsOperation in experiment
100% With ammonium carbamate In methanol at 20℃; a) To a solution of ethyl 2-oxocyclohexanecarboxylate (18.9 mL, 1 18 mmol) in methanol (120 mL) was added the ammonium carbamate (9.20 g, 1 18 mmol). The resulting mixture was stirred at rt for 1 h after which time the ammonium carbamate had completely dissolved. The reaction mixture was stirred for an additional 1 h before the volatiles were removed under reduced pressure to afford ethyl 2-aminocyclohexene- 1-carboxylate as a white-yellowish solid (19.9 g, quantitative yield). 1H NMR (400 MHz, CDCI3) δ 1.28 (t, J=7.2 Hz, 3H), 1.57 - 1.71 (m, 4H), 2.21 (t, J=6.1 Hz, 2H), 2.26 (t, J=6.1 Hz, 2H), 4.15 (q, J=7.2 Hz, 2H), 6.06 (br s, 2H)
97% With ammonia In methanol at 20℃; for 24 h; A mixture of ethyl 2-oxocyclohexanecarboxylate (32) (3.43 g, 20.2 mmol) and ca. 7 N ammonia solution in methanol (25 ml, ca. 175 mmol) was stirred in a closed vessel at room temperature for 24 h. The solvent was evaporated and the residue was dried in vacuo over P2O5 to give 3.30 g (97percent) of known31 compound 33 as yellow crystalline substance which was immediately utilized in the next step. 1H NMR (CDCl3) δ: 1.26 (t, J = 7.1 Hz, 3H), 1.55–1.67 (m, 4H), 2.16–2.27 (m, 4H), 4.13 (q, J = 7.1 Hz, 2H), 6.00 (br s, 2H). GCMS m/z: 169.1 M+.
90% With ammonia In methanol at 20℃; To 7N-ammonia-methanol solution, 170 g of ethyl 2-oxocyclohexanecarboxylate was added and stirred for an overnight at room temperature. Concentrating the solvent under reduced pressure, crude crystals were obtained, which were recrystallized from ethyl acetate-n-hexane to provide 152 g (90percent) of 2-aminocyclohex-1-enecarboxylic acid ethyl ester. 1H-NMR(CDCl3)δ:4.14(q,J=7.3Hz,2H),2.25(d,J=5.9Hz,2H), 2.20(d,J=5.9Hz,2H), 1.67~1.56(m,4H). Mass,m/e:169(M+),96(base)Into 7N-ammonia-methanol solution, 170 g of ethyl 2-oxocyclohexanecarboxylate was added and stirred for an overnight at room temperature. Distilling the solvent off under reduced pressure, the resulting crude crystalline product was recrystallized from ethyl acetate-n-hexane to provide 152 g (90percent) of ethyl 2-aminocyclohex-1- enecarboxylate. 1H-NMR(CDCl3):4.14(q,J=7.3Hz,2H),2.25(d,J=5.9Hz,2H), 2.20(d,J=5.9Hz,2H),1.67~1.56(m,4H) Mass,m/e:169(M+),96(base)
60% With ammonium acetate In methanol at 20℃; for 72 h; 5.2
Ethyl 2-aminocyclohex-1-ene-1-carboxylate (3b)
In the same manner as in the preparation of 3a, the title compound (32.3 g, 60percent) was obtained as a white solid from 2b (53.9 g, 0.317 mol).
1H NMR (DMSO-d6) δ 1.16 (3H, t, J = 7.1 Hz), 1.45-1.59 (4H, m), 2.09-2.21 (4H, m), 4.00 (2H, q, J = 7.1 Hz), 7.09 (2H, br s).

Reference: [1] Patent: WO2013/26900, 2013, A1, . Location in patent: Page/Page column 60
[2] New Journal of Chemistry, 2005, vol. 29, # 6, p. 769 - 772
[3] Tetrahedron Letters, 2013, vol. 54, # 9, p. 1133 - 1136
[4] Bioorganic and Medicinal Chemistry, 2014, vol. 22, # 14, p. 3654 - 3669
[5] Chemistry of Heterocyclic Compounds, 2006, vol. 42, # 6, p. 765 - 775
[6] Patent: EP1724267, 2006, A1, . Location in patent: Page/Page column 52; 68
[7] Bioorganic and Medicinal Chemistry, 2012, vol. 20, # 18, p. 5507 - 5517
[8] Helvetica Chimica Acta, 1945, vol. 28, p. 1684,1690
[9] Journal of the Indian Chemical Society, 1935, vol. 12, p. 299,305
[10] Justus Liebigs Annalen der Chemie, 1901, vol. 317, p. 104
[11] Justus Liebigs Annalen der Chemie, 1901, vol. 317, p. 104
[12] Journal of Organic Chemistry, 1978, vol. 43, p. 1460 - 1462
[13] Acta Chemica Scandinavica, 1997, vol. 51, # 6-7, p. 785 - 790
[14] Journal of the American Chemical Society, 2003, vol. 125, # 32, p. 9570 - 9571
[15] Advanced Synthesis and Catalysis, 2014, vol. 356, # 5, p. 1113 - 1118
  • 13
  • [ 7664-41-7 ]
  • [ 1655-07-8 ]
  • [ 1128-00-3 ]
Reference: [1] Justus Liebigs Annalen der Chemie, 1901, vol. 317, p. 104
  • 14
  • [ 1655-07-8 ]
  • [ 1128-00-3 ]
Reference: [1] Justus Liebigs Annalen der Chemie, 1901, vol. 317, p. 104
  • 15
  • [ 1655-07-8 ]
  • [ 3943-73-5 ]
  • [ 90536-71-3 ]
Reference: [1] Journal of the American Chemical Society, 2016, vol. 138, # 37, p. 12271 - 12277
  • 16
  • [ 1655-07-8 ]
  • [ 609-69-8 ]
Reference: [1] Helvetica Chimica Acta, 1980, vol. 63, p. 1383 - 1390
  • 17
  • [ 1655-07-8 ]
  • [ 389057-34-5 ]
Reference: [1] European Journal of Organic Chemistry, 2003, # 4, p. 721 - 726
  • 18
  • [ 1655-07-8 ]
  • [ 921602-83-7 ]
Reference: [1] Journal of Fluorine Chemistry, 2017, vol. 199, p. 60 - 66
Same Skeleton Products
Historical Records

Related Functional Groups of
[ 1655-07-8 ]

Aliphatic Cyclic Hydrocarbons

Chemical Structure| 843-59-4

[ 843-59-4 ]

Diethyl 2,5-dioxobicyclo[2.2.2]octane-1,4-dicarboxylate

Similarity: 0.97

Chemical Structure| 55704-60-4

[ 55704-60-4 ]

Diethyl 4-oxocyclohexane-1,1-dicarboxylate

Similarity: 0.94

Chemical Structure| 611-10-9

[ 611-10-9 ]

Ethyl 2-oxocyclopentanecarboxylate

Similarity: 0.94

Chemical Structure| 33668-25-6

[ 33668-25-6 ]

Ethyl 3-oxocyclohexane-1-carboxylate

Similarity: 0.94

Chemical Structure| 41302-34-5

[ 41302-34-5 ]

Methyl 2-oxocyclohexanecarboxylate

Similarity: 0.94

Esters

Chemical Structure| 843-59-4

[ 843-59-4 ]

Diethyl 2,5-dioxobicyclo[2.2.2]octane-1,4-dicarboxylate

Similarity: 0.97

Chemical Structure| 1115-30-6

[ 1115-30-6 ]

Diethyl 2-acetylsuccinate

Similarity: 0.97

Chemical Structure| 607-97-6

[ 607-97-6 ]

Ethyl 2-ethyl-3-oxobutanoate

Similarity: 0.97

Chemical Structure| 55704-60-4

[ 55704-60-4 ]

Diethyl 4-oxocyclohexane-1,1-dicarboxylate

Similarity: 0.94

Chemical Structure| 517-23-7

[ 517-23-7 ]

3-Acetyldihydrofuran-2(3H)-one

Similarity: 0.94

Ketones

Chemical Structure| 843-59-4

[ 843-59-4 ]

Diethyl 2,5-dioxobicyclo[2.2.2]octane-1,4-dicarboxylate

Similarity: 0.97

Chemical Structure| 1115-30-6

[ 1115-30-6 ]

Diethyl 2-acetylsuccinate

Similarity: 0.97

Chemical Structure| 607-97-6

[ 607-97-6 ]

Ethyl 2-ethyl-3-oxobutanoate

Similarity: 0.97

Chemical Structure| 55704-60-4

[ 55704-60-4 ]

Diethyl 4-oxocyclohexane-1,1-dicarboxylate

Similarity: 0.94

Chemical Structure| 517-23-7

[ 517-23-7 ]

3-Acetyldihydrofuran-2(3H)-one

Similarity: 0.94